Clinical Trials Logo

Purpura clinical trials

View clinical trials related to Purpura.

Filter by:

NCT ID: NCT00571467 Terminated - Clinical trials for Idiopathic Thrombocytopenic Purpura (ITP)

Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP

Start date: December 2007
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the safety of multiple doses of Staphylococcal protein A (PRTX-100) in adult patients with Idiopathic Thrombocytopenia Purpura (ITP). The pharmacokinetics, immunogenicity and pharmacodynamics will also be studied. Patients will be enrolled into 1 of 3 dose groups and receive 4 weekly IV doses of PRTX-100. A Safety Monitoring Committee will review safety data through Day 28 for the first 5 patients in a dose group before escalation to the next higher dose level. Patients will be followed for 8 weeks after dosing for safety, PK, immunogenicity and effect on platelet count(pharmacodynamics).

NCT ID: NCT00547066 Terminated - Clinical trials for Purpura, Thrombocytopenic, Idiopathic

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

Start date: November 2007
Phase: Phase 1/Phase 2
Study type: Interventional

This trial will study different dose levels of hA20 (IMMU-106) to see if they are safe and effective for treating ITP.

NCT ID: NCT00411801 Terminated - Clinical trials for Thrombotic Thrombocytopenic Purpura (TTP)

Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

Start date: May 2007
Phase: Phase 3
Study type: Interventional

Prior to the use of plasma products, thrombotic thrombocytopenic purpura (TTP) was usually a fatal condition. During plasma exchange therapy, patients need transfusion plasma that is blood group specific. Transfusing a patient with an incorrect blood group may have fatal consequences. Uniplas is a universally applicable human plasma, which can be administered irrespective of the patient's blood group. This study will test the safety and efficacy of Uniplas in comparison to cryosupernatant plasma in treatment of patients with TTP.

NCT ID: NCT00244257 Terminated - Clinical trials for Idiopathic Thrombocytopenic Purpura

Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Start date: August 2005
Phase: Phase 1
Study type: Interventional

This study is designed to investigate the safety of a single infusion of GMA161 in patients with idiopathic thrombocytopenic purpura, as well as, the way the drug enters and leaves the body. In addition, throughout the study, platelet counts and other blood cell numbers will be measured. NOTE: A decision was made to terminate this study in June 2008 due to low enrollment.

NCT ID: NCT00225875 Terminated - Clinical trials for Autoimmune Thrombocytopenic Purpura

Study of the Effectiveness of Rituximab in Adults With Chronic and Severe Immune Thrombocytopenic Purpura and Candidate for a Splenectomy

Start date: September 2003
Phase: Phase 2
Study type: Interventional

The goal of this study is to evaluate the clinical effectiveness of the rituximab at the adults with a chronic immune thrombocytopenic purpura (>=6 months of evolution) and severe (platelets <= 30x109/L) and candidate to a splenectomy. The objective is to obtain after a treatment by the rituximab a satisfactory response to one year, defined by a number of platelets higher than 50x109/L and at least 2 times superior with the persistent initial figure without treatment during one year after the end of the treatment.